Kamada (KMDA) Asset Writedowns and Impairment (2016 - 2025)
Kamada (KMDA) posted quarterly Asset Writedowns and Impairment of $1.3 million for Q2 2025, up 14.51% year-on-year from $1.2 million in Q2 2024, and up 14.51% on a QoQ basis from $1.2 million in Q2 2024.
Kamada (KMDA) Asset Writedowns and Impairment (2016 - 2025) Analysis & Trends
Kamada (KMDA) has reported Asset Writedowns and Impairment for 4 consecutive years, with $1.3 million the latest figure, recorded in Q2 2025.
- Quarterly Asset Writedowns and Impairment rose 14.51% year-over-year to $1.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.5 million (up 112.47% YoY) and the FY2024 annual result came in at $6.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment grew to $1.3 million in Q2 2025 per KMDA's latest filing, from $1.2 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for KMDA reached as high as $1.3 million in Q2 2025 and fell as low as $1.2 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Kamada | 400.07 Mn | 326.92 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Dec 31, 2017 | -3,000.00 |
| Dec 31, 2017 | -3,000.00 |
| Dec 31, 2016 | 5,000.00 |
| Dec 31, 2016 | 5,000.00 |
| Mar 31, 2016 | 10,000.00 |
| Mar 31, 2016 | 10,000.00 |